Dexamethasone implant in retinal vein occlusions

Sang Beom Han, Moosang Kim, Seung-Jun Lee Department of Ophthalmology, School of Medicine, Kangwon National University, Chuncheon, South KoreaWe read the article entitled “Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy” by W...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Han SB, Kim M, Lee SJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Dexamethasone retinal vein occlusion Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e6b22dced7634e66b236a612191607e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6b22dced7634e66b236a612191607e8
record_format	dspace
spelling	oai:doaj.org-article:e6b22dced7634e66b236a612191607e82021-12-02T00:15:00ZDexamethasone implant in retinal vein occlusions1177-5483https://doaj.org/article/e6b22dced7634e66b236a612191607e82016-08-01T00:00:00Zhttps://www.dovepress.com/dexamethasone-implant-in-retinal-vein-occlusions-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Sang Beom Han, Moosang Kim, Seung-Jun Lee Department of Ophthalmology, School of Medicine, Kangwon National University, Chuncheon, South KoreaWe read the article entitled “Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy” by Wallsh et al with great interest.1 The authors investigated the efficacy of the intravitreal dexamethasone (DEX) implant in patients with retinal vein occlusions (RVOs) who have failed multiple anti-vascular endothelial growth factor (anti-VEGF) injections. They concluded that DEX should be considered as a treatment option in patients with RVOs who have failed anti-VEGF therapy. We congratulate the authors for this well-organized study, and would like to contribute to their findings.View the original paper by Wallsh and colleagues.Han SBKim MLee SJDove Medical PressarticleDexamethasoneretinal vein occlusionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 1585-1586 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dexamethasone retinal vein occlusion Ophthalmology RE1-994
spellingShingle	Dexamethasone retinal vein occlusion Ophthalmology RE1-994 Han SB Kim M Lee SJ Dexamethasone implant in retinal vein occlusions
description	Sang Beom Han, Moosang Kim, Seung-Jun Lee Department of Ophthalmology, School of Medicine, Kangwon National University, Chuncheon, South KoreaWe read the article entitled “Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy” by Wallsh et al with great interest.1 The authors investigated the efficacy of the intravitreal dexamethasone (DEX) implant in patients with retinal vein occlusions (RVOs) who have failed multiple anti-vascular endothelial growth factor (anti-VEGF) injections. They concluded that DEX should be considered as a treatment option in patients with RVOs who have failed anti-VEGF therapy. We congratulate the authors for this well-organized study, and would like to contribute to their findings.View the original paper by Wallsh and colleagues.
format	article
author	Han SB Kim M Lee SJ
author_facet	Han SB Kim M Lee SJ
author_sort	Han SB
title	Dexamethasone implant in retinal vein occlusions
title_short	Dexamethasone implant in retinal vein occlusions
title_full	Dexamethasone implant in retinal vein occlusions
title_fullStr	Dexamethasone implant in retinal vein occlusions
title_full_unstemmed	Dexamethasone implant in retinal vein occlusions
title_sort	dexamethasone implant in retinal vein occlusions
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/e6b22dced7634e66b236a612191607e8
work_keys_str_mv	AT hansb dexamethasoneimplantinretinalveinocclusions AT kimm dexamethasoneimplantinretinalveinocclusions AT leesj dexamethasoneimplantinretinalveinocclusions
_version_	1718403898209730560

Dexamethasone implant in retinal vein occlusions

Ejemplares similares